BioWorld

Sep. 5, 2003

Epimmune Trimming Staff, Costs To Help Develop Pipeline Drugs

Epimmune Inc. reduced its staff by 23 percent and implemented other cost-cutting measures that the company said would give it enough operating funds to pull results from ongoing clinical trials in HIV and cancer. (BioWorld Today) Read More

Theratechnologies Enters Deal With J&J In Area Of Diabetes

Vaccine Spurs Immune System To Attack B. anthracis Plus Its Toxins, Beating Current Vaccines

Pozen Licenses MT 300 Rights To Xcel In Deal Worth At Least $10M

Cerus, Baxter Stop Phase III Of S-303 In Precautionary Move

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 18, 2025.

Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

HIV research is close to a cure but far from ending the pandemic

BioWorld

Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...

Maintenance, man: Lilly’s phase III weight trial hits goals

BioWorld

Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...

Insilico CEO Alex Zhavoronkov and the automated lab’s humanoid that runs all preclinical tests in the Hong Kong lab.

AI drug developer Insilico to raise $292 million in Hong Kong IPO

BioWorld

Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...